New Book Empowers Dementia Care Partners to Navigate Challenges with Confidence and Calm
Grounded in Olson's extensive expertise and compassionate approach, 'Making Peace with Dementia' redefines how care partners approach their roles. The book highlights a pivotal yet surprising truth: mastering dementia care depends less on changing the individual with dementia and more on equipping care partners with practical strategies to manage and reduce stress.
The guide is divided into three core sections designed to empower care partners by exploring techniques for creating calm in their loved ones, cultivating a supportive environment, and finding personal clarity and balance. Olson's conversational and relatable style makes complex concepts accessible, helping readers sustain their energy, improve communication, and prepare for the future with pragmatic expectations.
'Families caring for loved ones with dementia often feel overwhelmed and lost,' says Olson. 'This book is my way of helping them discover that by learning practical strategies and rethinking their approach, they can create a more meaningful and peaceful experience for everyone involved.'
Ann Olson's professional background in treating neurological conditions, combined with her work as a dementia educator, coach, and senior living consultant, makes her uniquely positioned to offer this much-needed resource. Additionally, in 2022, Olson founded Sweet Basil Senior Care, an organization dedicated to supporting families navigating life with dementia.
The book is an invaluable resource for anyone seeking to enhance their caregiving skills, reduce tension, and rediscover joy in their relationships with those impacted by dementia.
'Making Peace with Dementia' (ISBN: 9781966074953 / 9781966074946) can be purchased through retailers worldwide, including Amazon and Barnes & Noble. The hardcover retails for $29.99, the paperback retails for $19.99, and the ebook retails for $2.99. Review copies and interviews with the author are available upon request.
For more information or to purchase the book, visit Amazon.
From the Back Cover:
Making Peace with Dementia was written for the dementia care partner who often is thrust into a difficult situation and struggles to provide care at the cost of their own health and happiness.
Author Ann Olson, an expert with decades of experience in dementia care, provides you with practical, easy-to-read guidance. Her book offers insight into the changes associated with dementia and equips you with strategies to side-step conflict, communicate effectively, and enhance safety and engagement.
Through real-life examples, Olson illustrates realistic and successful approaches for managing a variety of challenging situations. Numerous techniques are shared to help you prioritize your well-being and navigate dementia with greater calm, confidence and peace of mind.
About the Author
Ann Olson, OTR/L, is an occupational therapist specializing in neurological conditions, including dementia. Over her 25-year career, she has worked as a senior living consultant, educator, and dementia caregiver coach. Olson is also the founder of Sweet Basil Senior Care. She lives in Minneapolis, Minnesota, with her husband and dog, Violet.
About MindStir Media:
MindStir Media LLC is an award-winning book publisher. To learn more about publishing a book with MindStir Media, visit http://mindstirmedia.com or call 800-767-0531.
Michelle VanSledright
MindStir Media LLC
+1 800-767-0531
email us here
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
GE HealthCare launches new advanced digital X-ray system to enable access and increase efficiency in high throughput settings
Definium™ Pace Select ET, a new floor-mounted digital X-ray system, enables access to affordable, high-quality medical imaging technology while easing workflow burdens in high-volume environments This new X-ray system, designed to act as a personal assistant for technologists, provides automation of in-room workflows and motorization of manual, repetitive tasks to increase throughput and reduce technologist learning curve CHICAGO, July 24, 2025--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), today announced commercial availability of an advanced floor-mounted digital X-ray system, Definium™ Pace Select ET1, designed to deliver high-image quality and optimize efficiency in highly demanding environments while enhancing access and affordability. X-ray exams often serve as the entry point to diagnostic imaging, accounting for 60% of all imaging studies conducted, resulting in an ever-increasing workload for radiologists and technologists2 3. This increased demand, combined with acute staffing challenges where 80% of healthcare organizations are short-staffed and radiology technologists have the highest vacancies3, high burnout levels and work-related injuries, creates critical barriers to providing timely, effective diagnostic imaging for patients in need of X-ray imaging. GE HealthCare's new Definium Pace Select ET solves for many of these challenges by automating manual, repetitive steps and helping to reduce physical strain. The system leverages AI to ensure accurate patient positioning and consistent image quality across various clinical conditions while streamlining the technologist workflow to maximize the patient experience and throughput. "Burdened with the stress and pressure to keep radiology departments running smoothly and profitably, we aim to empower technologists with a system that consistently makes the first image count," said Sharad Sharma, Global General Manager, X-ray, at GE HealthCare. "With its advanced digital capabilities and automation, Definium Pace Select ET allows technologists of all experience levels to deliver consistent high-quality images to serve the full range of anatomies and patient populations." Easy-to-use features allow technologists to focus on patient care Building on the trusted Definium platform from GE HealthCare, the Definium Pace Select ET system brings advanced automation and workflow features to a flexible, floor-mounted system with elevating table, in-room exam control, and common user interface to assist technologists. "This launch reinforces our commitment to provide accessible, efficient, and high-quality care for patients, while alleviating stress from the technologist's workday by minimizing repetitive tasks and automating steps," said Jyoti Gupta, PhD, President & CEO of Women's Health and X-ray at GE HealthCare. "We remain dedicated to advancing our technology through transformative digital and AI-enabled capabilities that will remove barriers to timely and effective diagnostic imaging for any patient in need of X-ray imaging." The Definium Pace Select ET system brings the same high image quality typically seen in more expensive overhead tube suspension (OTS) systems to the affordability focused floor-mounted market. Designed and developed with extensive customer feedback, the system brings: Advanced automation to reduce workflow steps and physically demanding movements for technologists, potentially minimizing work-related injuries. Image variability reduction through the AI-enabled Helix™ Advanced Image Processing to provide consistent high-quality images. Prevention of errors before they occur through automated positioning, protocol selection, patient size (body habitus), and collimation via the Intelligent Workflow Suite, and a quality check prior to radiation exposure. To learn more about the new X-ray system, visit About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. _______________________________ 1 510(k) cleared. Not CE marked. Cannot be placed on the market or put into service or used with human beings until it has been made to comply with CE marking and/or regulatory approval. Not all features available in all markets. 2 MV 2019 X-ray CR / DR Market Outlook Report) page 9, 37 3 Pearson, Dave. "Radiology techs in especially high demand as 85% of hospitals seek 'allied' health workers", 23 Oct. 22. View source version on Contacts GE HealthCare Media Contact: Katie ScrivanoM +1 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fox News
an hour ago
- Fox News
The new world of medicine: AI doctors
Doctronic founders Dr. Adam Oskowitz and Matt Pavelle discuss their new AI tool to help users better 'understand their health' and communicate with their doctors on 'America Reports.'
WebMD
an hour ago
- WebMD
FDA OKs New Steroid-Free Skin Cream for Hand Eczema
July 24, 2025 – The FDA has approved a new treatment as the first and only skin cream for a specific type of hand eczema that affects about 1 in every 10 people globally. The cream, sold under the name Anzupgo, contains a new drug called delgocitinib and is for adults with long-term or chronic hand eczema (CHE), especially if steroid creams don't help or aren't a good option. CHE is a type of eczema that affects hands and wrists, causing the skin to become dry, itchy, sore, blistered, thick, or swollen. It can last for at least three months and flares up at least twice a year. CHE develops when the skin's protective barrier is damaged, leading to inflammation and changes in the naturally existing skin bacteria. CHE can seriously affect daily life and mental health as around 70% of people with severe CHE find it hard to do everyday tasks. Currently available treatments often provide only temporary relief, may cause side effects with long-term use, and may need to be injected, highlighting the need for effective and easy-to-use options. Anzupgo was tested in two studies with about 960 people who had moderate to severe CHE. They used either Anzupgo or a placebo cream twice a day for 16 weeks. More people who used Anzupgo had clear or almost clear skin (20% and 29%) compared to those who used the fake cream (10% and 7%). In a longer follow-up study, about 30% of patients using Anzupgo continued to see improvement after 36 weeks. Overall, the treatment was well-tolerated. Less than 1% of people reported side effects like mild skin pain, tingling, itching, redness, or skin infections. A few also had low white blood cell counts. Anzupgo, made by the drugmaker Leo Pharma, is a steroid-free cream that works by blocking key signals from specific proteins in the immune system known as JAK, which cause inflammation in the skin when overactivated. This helps reduce flare-ups and relieve symptoms. Patients can easily apply the cream to the affected areas only on their hands and wrists, following their doctor's advice, and avoid touching their mouth and eyes. The FDA advises against using Anzupgo alongside other medications that work in a similar way or suppress the immune system, as this could raise the risk of side effects. People using Anzupgo should also avoid live vaccines right before, during, and shortly after treatment. Breastfeeding women are told not to touch their nipple area after applying the cream to their hands or wrists. Doctors should be informed of any ongoing or frequent infections, as well as any other health conditions that might increase the risk of infection during treatment.
